Group 1 - The company expects to report a net loss attributable to shareholders of the parent company for the year 2025, estimated between -65 million yuan and -55 million yuan [3] - The net profit attributable to shareholders of the parent company, after deducting non-recurring gains and losses, is projected to be between -82 million yuan and -69 million yuan [4] - The previous year's net profit attributable to shareholders of the parent company was -49.53 million yuan, indicating a worsening financial performance [6] Group 2 - The increase in operating income is attributed to growth in the CDMO segment, with a slight rise in overall gross profit margin [7] - The company has reduced period expenses year-on-year due to cost-cutting measures, which has led to a decrease in net loss attributable to shareholders after excluding non-recurring items [7] - The increase in asset impairment losses is due to the company's cautious approach in testing assets for impairment and making provisions accordingly [7]

Group 1 - The company expects a negative net profit for the fiscal year 2025, covering the period from January 1, 2025, to December 31, 2025 [1] - The preliminary performance forecast data has not been audited by the accounting firm, but there are no significant disagreements between the company and the accounting firm regarding the performance forecast [1][2] Group 2 - The main reasons for the performance change include: 1. The environmental protection industry cycle and intensified market competition have compressed the profit margins, leading to a decline in gross profit margin [2] 2. Changes in the aging of receivables have resulted in increased credit impairment losses [2] 3. The termination of the contract for the Ampara D project in Uttar Pradesh, India, due to unilateral actions by the owner and local policy changes, has led to increased guarantee payments and asset impairment losses [2] Group 3 - The performance forecast data is preliminary and the specific financial data will be confirmed in the company's 2025 annual report [3]

Core Viewpoint - Tianqi Lithium Industries, Inc. is expected to report a positive net profit for the year 2025, indicating a turnaround from previous losses [2]. Group 1: Performance Forecast - The performance forecast period is from January 1, 2025, to December 31, 2025 [1]. - The company anticipates a positive net profit, indicating a turnaround from previous losses [2]. Group 2: Communication with Auditors - The financial data related to the performance forecast has not yet been audited by the accounting firm [2]. - There are no significant disagreements between the company and the auditors regarding the performance forecast as of the announcement date [2]. Group 3: Reasons for Performance Changes - Despite fluctuations in the lithium product market leading to a decrease in sales prices compared to the previous year, the company benefits from a shortened pricing cycle for lithium ore from its subsidiary Windfield Holdings Pty Ltd [3]. - The pricing mechanism for chemical-grade lithium concentrate from its wholly-owned subsidiary Talison Lithium Pty Ltd has aligned more closely with the sales pricing mechanism for lithium chemical products, reducing previous discrepancies [3]. - The company expects significant growth in investment income from its joint venture, Sociedad Química y Minera de Chile S.A. (SQM), based on Bloomberg's forecast for SQM's earnings per share for Q4 2025 [3]. - The Australian dollar has strengthened against the US dollar, resulting in increased foreign exchange gains compared to 2024 [4]. - The company plans to conduct impairment tests on assets showing signs of impairment as of the balance sheet date, with preliminary estimates indicating a decrease in impairment losses compared to 2024 [4].

Core Viewpoint - The company expects a significant increase in net profit for the year 2025, with projections ranging from 110 million to 138 million yuan, representing a year-on-year growth of 36.93% to 71.78% [2]. Group 1: Performance Forecast - The performance forecast period is from January 1, 2025, to December 31, 2025 [1]. - The profit forecast is based on preliminary calculations by the company's finance department and has not yet been audited by an external accounting firm [1][2]. Group 2: Reasons for Performance Change - The expected increase in net profit is attributed to a reduction in R&D expenses compared to the previous year, primarily due to fewer new projects in generic drug development and delays in the internal approval process for a strategic cooperation agreement with a partner company [2]. - Despite a significant decline in sales volume for certain products due to low demand and price drops, the company's formulation business has seen rapid growth driven by new product launches and successful bidding in centralized procurement [2].

Group 1 - The company expects a significant decline in net profit, projecting a decrease of over 50% for the fiscal year 2025 [1] - The performance forecast period is from January 1, 2025, to December 31, 2025, with net profit anticipated to be positive but substantially lower than the previous year [1] - The company has communicated with its accounting firm regarding the performance forecast, and there are no discrepancies noted, pending the final audit results [1] Group 2 - The decline in revenue is attributed to increased market competition and changes in market demand, which have also led to a decrease in product prices [1] - Financial expenses have increased significantly year-on-year, primarily due to foreign exchange losses resulting from currency fluctuations, further impacting profit levels [1]

Group 1 - The company expects a positive net profit for the year 2025, indicating an upward trend in performance [2] - The performance forecast period is from January 1, 2025, to December 31, 2025 [1] - The financial data related to the performance forecast is based on preliminary estimates by the company's finance department and has not been audited by the accounting firm [5] Group 2 - The company has actively faced market challenges by focusing on internal improvements and enhancing operational efficiency, which has contributed to increased profitability [4] - Financial expenses have decreased compared to the previous year, primarily due to a net reduction in loan balances and lower financing costs resulting from the continuous decline in the Loan Prime Rate (LPR) [4] - The company has completed the impairment provision for goodwill related to Zhaosheng Environmental Protection in 2024, and it will not be involved in 2025 [4]

Group 1 - The company expects a positive net profit for the year 2025, but anticipates a decline of over 50% compared to the previous year [2] - The financial data for the performance forecast is based on preliminary calculations by the company's finance department and has not been audited by an accounting firm [2][3] - The decline in net profit is attributed to changes in the international macroeconomic and trade environment, which have led to adjustments in product structure and a decrease in gross profit margin [3] Group 2 - The performance forecast period is from January 1, 2025, to December 31, 2025 [1] - The company has communicated with the accounting firm regarding the performance forecast and there are no discrepancies in this regard [2]

Core Viewpoint - The company, Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd., forecasts significant growth in revenue for the year 2025, alongside a reduction in research and development expenses, while still expecting a net loss that is less severe than the previous year [2][7]. Group 1: Performance Forecast - The company anticipates 2025 annual revenue between 209.45 million and 250.88 million yuan, representing an increase of 179.35 million to 220.78 million yuan compared to the previous year, with a year-on-year growth rate of 595.96% to 733.62% [2]. - Expected R&D expenses for 2025 are projected to be between 425.21 million and 519.70 million yuan, a decrease of 90.09 million to 184.58 million yuan from the previous year, reflecting a year-on-year reduction of 14.77% to 30.27% [2]. - The forecasted net loss attributable to the parent company for 2025 is estimated to be between 480.64 million and 587.45 million yuan, which is a reduction of 209.83 million to 316.64 million yuan compared to the previous year, indicating a year-on-year decrease of 26.32% to 39.71% [2]. - The net loss attributable to the parent company after deducting non-recurring gains and losses is expected to be between 523.63 million and 630.44 million yuan, with a reduction of 173.89 million to 280.70 million yuan compared to the previous year, reflecting a year-on-year decrease of 21.62% to 34.90% [2]. Group 2: Previous Year Performance - In 2024, the company achieved a revenue of 30.10 million yuan [3]. - The R&D expenses for 2024 were recorded at 609.79 million yuan [4]. - The net loss attributable to the parent company for 2024 was 797.27 million yuan [5]. - The net loss attributable to the parent company after deducting non-recurring gains and losses for 2024 was 804.33 million yuan [6]. Group 3: Reasons for Performance Changes - The significant increase in revenue is attributed to the steady growth in sales of the company's first commercial product, the Saliqi monoclonal antibody injection, and the recognition of licensing income from the GR1803 injection licensing agreement [7]. - The company has maintained high levels of R&D investment while advancing multiple projects into clinical research stages, with core products entering critical clinical trial phases. The absence of share-based payment expenses in 2025, due to the completion of the stock incentive plan for the core team in 2024, has also contributed to the reduction in expenses [7].

Group 1 - The company expects to achieve a net profit attributable to shareholders of approximately 11 million yuan for the year 2025, marking a turnaround from a loss in the previous year [3] - The company anticipates a net profit attributable to shareholders, excluding non-recurring gains and losses, of approximately -7.6 million yuan for the year 2025 [4] - The previous year's financial performance showed a net loss attributable to shareholders of 50.38 million yuan and a net loss of 59.87 million yuan after excluding non-recurring gains and losses [6] Group 2 - The company aims to optimize its business structure and product matrix, focusing on high-quality projects to drive revenue growth in 2025 [7] - Non-recurring gains and losses are expected to positively impact the net profit, estimated at around 18.6 million yuan, primarily from government subsidies and investment income [7] - Despite revenue growth, the company anticipates a negative net profit after excluding non-recurring gains and losses due to market competition and declining gross margins [7]

截至2026年1月29日收盘，ST得润(002055)报收于5.79元，下跌1.53%，换手率4.45%，成交量26.44万 手，成交额1.55亿元。 当日关注点 交易信息汇总 资金流向 1月29日主力资金净流出28.84万元；游资资金净流出751.43万元；散户资金净流入780.27万元。 公司公告汇总 2025年度业绩预告 深圳市得润电子股份有限公司发布2025年度业绩预告，预计归属于上市公司股东的净利润为-4,000万元 至-2,500万元，扣除非经常性损益后的净利润为2,800万元至4,000万元。业绩较上年同期大幅减亏，主 要因主营业务健康发展、聚焦连接器业务、原控股子公司不再并表减少亏损影响。同时，公司因收到证 监会行政处罚事先告知书及投资者诉讼事项计提预计负债，对利润造成较大负面影响。本次业绩预告未 经审计，最终数据以2025年度报告为准。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自【交易信息汇总】：1月29日主力资金净流出28.84万元，游资资金净流出751.43万元，散户资 金净流入780.27万元。 来 ...